undefined

Sponsors

 

PLATINUM SPONSOR

 

   
                        undefined

Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company which engineers targeted immunotherapies, seeking to improve patient outcomes through the power of innate immunity. Affimed’s fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. We are developing single and combination therapies to treat cancers. For more information, please visit www.affimed.com.

   
 

GOLD SPONSOR

     
                                                                                                                             undefined

Glycostem is a clinical-stage company, leader in Natural Killer (NK) cell commercialization, harvesting the power of allogeneic cells like Natural Killer (NK) cells - oNKord® - in the field of cellular immunotherapy. Over the last 10+ years staff at Glycostem has innovated, developed and clinically tested naked NK-cells as one of the first companies worldwide. Using its proprietary expansion and differentiation platform, Glycostem produces large amounts of effector cells from Umbilical Cord Blood stem cells. Products are composed of high-quality, pure and active cells.

   
               undefined

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Our more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 2,500 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

   
  undefined

Innate Pharma S.A. is a fully integrated oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a landmark and multi-products partnership with AstraZeneca/Medimmune.

                                                                                                                                                                                                                                                                                                      
 

SILVER SPONSOR

     
  undefined

JLB publishes original experimental and clinical research that provides new insights into the function of leukocytes and/or stromal cells at the molecular, structural, cellular and systemic level.  The Journal scope includes all leukocytes and/or leukocyte products, together with associated stromal cells studied in vitro and in the context of innate and adaptive immunity, development, homeostasis, host-pathogen interactions, immunotherapy, and immunopathogenesis.

   
 

          

            undefined

 

Bio-Techne® unites some of the most distinguished brands within Life Sciences including R&D Systems®, Novus Biologicals®, Tocris®, ProteinSimple® and Advanced Cell Diagnostics®. Together we deliver innovative research technologies and high-quality reagents to the field of Immunology. Our brands work collaboratively to support researchers by providing the instruments, custom manufacturing, and testing services they require to further scientific discovery.

   
  undefined

CellGenix is a leading global supplier of high quality raw materials for the expanding cell and gene therapy space. We develop, manufacture and market human cytokines and growth factors in preclinical and GMP quality along with GMP serum-free media for further manufacturing of ATMPs. We offer our products in combination with expert regulatory and technical support to ensure a seamless transition from research to commercialization.

   
 

BRONZE SPONSOR

     
          undefined Headquartered on the campus of the Moffitt Cancer Center, Tampa, Florida, Vycellix™, Inc., is a closely-held immunotherapy-focused, discovery company with the mission to fundamentally impact the challenges that currently prevail in the area of cell & gene based-therapies.  The Company is engaged in the development of proprietary approaches for cell-based immunotherapeutic products and to improve patient outcomes.  Vycellix is leveraging its assets to develop an early-stage pipeline of multifaceted, next-generation NK cell therapies targeting hematological malignancies and solid tumors, including its RONK™ (Retargeted Optimized NK cell) therapy.     
               undefined Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. Frontiers in Immunology is an open-access journal at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. The journal is led by Field Chief Editor Dr. Luigi Daniele Notarangelo, who is supported by an outstanding Editorial Board of international researchers. For more information, visit https://www.frontiersin.org/journals/immunology and follow @FrontImmunol on Twitter.     
  undefined The European Federation of Immunological Societies (EFIS) is a non-profit umbrella organization that represents 33 European immunology societies. The main goals of EFIS are to support immunological research and education, as well as to strengthen scientific interaction amongst its members. Together with its partner official journals, the European Journal of Immunology and Immunology Letters, EFIS focuses especially on supporting young scientists, e.g., through fellowships or travel grants.